Probing Mutant KRAS, STK11, KEAP1 in NSCLC

Abstract According to an exploratory analysis of data from the POSEIDON trial, patients with non–small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings.